Phathom Pharmaceuticals, Inc. (PHAT) financial statements and ratios from SEC XBRL: revenue $0.3B (TTM), net margin -126.3%, revenue growth 216.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $175.11M |
| Revenue (TTM) | $0.3B |
| Net Margin | -126.3% |
| Operating Margin (TTM) | 8.4% |
| Net Debt / EBITDA | -0.8 |
| Revenue Growth (YoY) | 216.9% |
| EPS Growth (YoY) | -42.7% |
| FCF Growth (YoY) | -37.4% |
| Price / Sales | 2.99 |
| FCF Yield | -29.4% |
| Altman Z-Score | -8.33 (distress) |
| Piotroski F-Score | 4/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
PHAT overview · PHAT earnings · PHAT KPIs · PHAT documents · PHAT ownership · PHAT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.